Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Pier Luigi Zinzani, Paolo Corradini, Andrea Gallamini, Alberto Grossi, Mario Lazzarino, Monia Marchetti, Maurizio Martelli, Giuseppe Rossi & Umberto Vitolo. (2012) Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leukemia & Lymphoma 53:5, pages 789-795.
Read now
Read now
Fernando Roncolato, Anna Gazzola, Pier Luigi Zinzani, Stefano A Pileri & Pier Paolo Piccaluga. (2011) Targeted molecular therapy in peripheral T-cell lymphomas. Expert Review of Hematology 4:5, pages 551-562.
Read now
Read now
Jennifer E. Amengual & Bruce G. Raphael. (2010) Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma. Leukemia & Lymphoma 51:7, pages 1347-1350.
Read now
Read now
Eva Geissinger, Irina Bonzheim, Sabine Roth, Andreas Rosenwald, Hans Konrad Müller-Hermelink & Thomas Rüdiger. (2009) CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leukemia & Lymphoma 50:6, pages 1010-1016.
Read now
Read now
Kevin Boyd & Claire E Dearden. (2008) Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Review of Anticancer Therapy 8:4, pages 525-533.
Read now
Read now
Articles from other publishers (19)
Ling He, Na Chen, Lei Dai & Xingchen Peng. (2023) Advances and challenges of immunotherapies in NK/T cell lymphomas. iScience 26:11, pages 108192.
Crossref
Crossref
Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo & Qing-Qing Cai. (2023) Novel target and treatment agents for natural killer/T-cell lymphoma. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Daniel Ren Yi Yap, Jing Quan Lim, Dachuan Huang, Choon Kiat Ong & Jason Yongsheng Chan. (2023) Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma. Frontiers in Immunology 14.
Crossref
Crossref
Celeste Sánchez-Romero, Ronell Bologna-Molina, Oslei Paes de Almeida, Alan Roger Santos-Silva, Ana Carolina Prado-Ribeiro, Thaís Bianca Brandão & Román Carlos. (2021) Extranodal NK/T cell lymphoma, nasal type: An updated overview. Critical Reviews in Oncology/Hematology 159, pages 103237.
Crossref
Crossref
Pamela B. Allen & Mary Jo Lechowicz. (2019) Management of NK/T-Cell Lymphoma, Nasal Type. Journal of Oncology Practice 15:10, pages 513-520.
Crossref
Crossref
Rena Buckstein, Graeme Fraser, Matthew Cheung, Vishal Kukreti, John Kuruvilla, Kevin Imrie, Eugenia Piliotis, Gregory Pond, Jolanta Windsor, Zeina Ghorab, Kevin Shuoprasad, Ruth Turner, Ralph M. Meyer, Kathy Pritchard, Scott Walker, Mark Levine & Michael Crump. (2016) Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. Clinical Lymphoma Myeloma and Leukemia 16:1, pages 18-28.e4.
Crossref
Crossref
Mehdi Hamadani, Sarah M. Abu Kar, Saad Z. Usmani, Bipin N. Savani, Ernesto Ayala & Mohamed A. Kharfan-Dabaja. (2014) Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas. Seminars in Hematology 51:1, pages 73-86.
Crossref
Crossref
Pier Paolo Piccaluga & Stefano A. Pileri. 2013. Lymphoma. Lymphoma
53
63
.
Pier Paolo Piccaluga & Stefano Aldo Pileri. 2013. T-Cell Lymphomas. T-Cell Lymphomas
41
56
.
Stefano A. Pileri & Pier Paolo Piccaluga. (2012) New molecular insights into peripheral T cell lymphomas. Journal of Clinical Investigation 122:10, pages 3448-3455.
Crossref
Crossref
Bettina Bisig, Philippe Gaulard & Laurence de Leval. (2012) New biomarkers in T-cell lymphomas. Best Practice & Research Clinical Haematology 25:1, pages 13-28.
Crossref
Crossref
Seok Jin Kim, Kihyun Kim, Yong Park, Byung Soo Kim, Jooryung Huh, Young Hae Ko, Keunchil Park, Cheolwon Suh & Won Seog Kim. (2010) Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Investigational New Drugs 30:1, pages 368-375.
Crossref
Crossref
Arnaud Jaccard & Olivier Hermine. (2011) Extranodal natural killer/T-cell lymphoma. Current Opinion in Oncology 23:5, pages 429-435.
Crossref
Crossref
Jew Win Kuan, Kian Meng Chang, Ngee Siang Lau, Purushothaman Visalachy, Sen Mui Tan, Tee Chuan Ong & Anselm Ting Su. (2011) The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. Indian Journal of Hematology and Blood Transfusion 27:3, pages 136-145.
Crossref
Crossref
H.C. Kluin-Nelemans, M. van Marwijk Kooy, P.J. Lugtenburg, W.L.J. van Putten, M. Luten, J. Oudejans & G.W. van Imhoff. (2011) Intensified alemtuzumab–CHOP therapy for peripheral T-cell lymphoma. Annals of Oncology 22:7, pages 1595-1600.
Crossref
Crossref
Claire E. Dearden, Rod Johnson, Ruth Pettengell, Stephen Devereux, Kate Cwynarski, Sean Whittaker & Andrew McMillan. (2011) Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma). British Journal of Haematology 153:4, pages 451-485.
Crossref
Crossref
Emilio Iannitto, Andrés J.M. Ferreri, Viviana Minardi, Claudio Tripodo & Hans H. Kreipe. (2008) Angioimmunoblastic T-cell lymphoma. Critical Reviews in Oncology/Hematology 68:3, pages 264-271.
Crossref
Crossref
C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini & S A Pileri. (2008) Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. Journal of Clinical Pathology 61:11, pages 1160-1167.
Crossref
Crossref
Eva Kimby. (2007) Management of advanced-stage peripheral T-cell lymphomas. Current Hematologic Malignancy Reports 2:4, pages 242-248.
Crossref
Crossref